Arkolith/Insider Trading/KALV/Form 4

Yea Christopher

CHIEF DEVELOPMENT OFFICERKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed May 29, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$905K
Net Open-Market Flow
-$905K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)34K$7.07$239K264K
May 27, 2026Sell(S)34K$26.78$905K230K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)34K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001691102-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML